Beam Therapeutics (NASDAQ:BEAM) just reported results for the first quarter of 2024.
- Beam Therapeutics reported earnings per share of -$1.21. This was above the analyst estimate for EPS of -$1.42.
- The company reported revenue of $7.41 million.
- This was 56.33% worse than the analyst estimate for revenue of $16.97 million.